Crocs, Inc. filings document the operations, governance and capital structure of a branded casual footwear company built around the Crocs and HEYDUDE brands. Form 8-K reports furnish earnings releases covering revenue, channel performance, gross margin, non-GAAP reconciliations, outlook commentary, cash flow, share repurchases and debt activity.
Proxy materials cover annual meeting matters, board and executive compensation disclosures, equity award information and pay-versus-performance data. Other material-event filings describe executive appointments and related compensatory arrangements, providing formal records of leadership and governance changes within the company.
Crocs, Inc. reported that EVP, Chief Financial Officer Reagan Patraic had 4,701 common shares withheld by the issuer on September 22, 2026, to cover tax withholding obligations upon vesting of a restricted stock unit award. The reported per-share price was $124.58, and direct holdings following the transaction were 81,370 shares. No Rule 10b5-1 plan is reported.
Crocs, Inc. (CROX) director Thomas J. Smach reported an open-market or private purchase of 680 shares of common stock on September 15, 2026 at $111.49 per share, held indirectly through Smach Family Investments, LLC.
After this transaction, he reports 93,249 shares held directly, 112,063 shares held indirectly by trust where he exercises voting and investment power, 6,416 shares held indirectly by his spouse, and 680 shares held indirectly via Smach Family Investments, LLC, with beneficial ownership of the LLC shares disclaimed except to the extent of his pecuniary interest. No Rule 10b5-1 trading plan is reported.
Crocs, Inc. (CROX) reported that director Beth J. Kaplan purchased 885 shares of common stock on September 15, 2026 in a purchase in open market or private transaction at an average price of $112.1215 per share. Following this transaction, she directly holds 15,259 shares of Crocs common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Crocs, Inc. (CROX) director Thomas J. Smach reported open-market purchases of a total of 4,000 shares of Common Stock on September 10, 2026. These included 1,000 shares bought indirectly through a family trust and 3,000 shares bought in his direct account. No Rule 10b5-1 trading plan is reported. After these transactions, he reports 93,249 shares held directly, 112,063 shares held via a trust over which he has voting and investment power, and 6,416 shares held indirectly through his spouse.
Crocs, Inc. reported that a trust associated with Chief Executive Officer Andrew Rees sold a total of 30,000 shares of common stock on August 7 and 10, 2026 in open-market transactions. The weighted-average sale prices came from ranges between $136.78 and $140.05 per share. A separate entry shows Rees holding 570,179 shares of common stock directly as of August 7, 2026.
Crocs, Inc. (CROX) received a Form 144 notice indicating an intention to sell 19,072 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on or after August 10, 2026 on NASDAQ. The shares relate to previously granted Performance Stock Units and Restricted Stock issued as compensation. Related entities, including The Rees Family Living Trust and The Rees Family Foundation, sold additional common shares in the prior three months.
CROX has a planned sale of restricted or control securities under Rule 144. An affiliated holder intends to sell 10,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an estimated aggregate value of $1,376,400.00 on NASDAQ as of 08/07/2026.
The filing also lists prior sales within the last three months by related entities: 32,688 common shares for $3,860,282.82 by The Rees Family Living Trust on 06/05/2026, and 5,000 common shares for $538,418.00 by The Rees Family Foundation, Inc. on 05/21/2026. The 10,000 shares to be sold relate to Performance Stock Units granted on 03/17/2020 as compensation.
Crocs, Inc. insider filing indicates a planned sale of 10,928 shares of common stock through Morgan Stanley Smith Barney LLC on or about 08/07/2026 on NASDAQ, with an aggregate market value of $1,508,248.20. The filing notes 47,945,075 shares of common stock outstanding. The shares derive from Performance Stock Units granted in 2021 and 2024 as compensation. Recent sales over the past three months include 32,688 shares sold for $3,860,282.82 by The Rees Family Living Trust and 5,000 shares sold for $538,418.00 by The Rees Family Foundation, Inc.
Crocs, Inc. CEO Andrew Rees exercised 200,000 employee stock options on August 4, 2026 at an exercise price of $6.98 per share, receiving 200,000 shares of common stock. The issuer withheld 105,610 shares at $141.19 per share to cover the exercise price and tax obligations. A family trust for which Rees is trustee holds 743,293 shares of Crocs common stock with voting and investment power, and the transactions were not made under a Rule 10b5-1 trading plan.
FMR LLC and Abigail P. Johnson report beneficial ownership of common stock of Crocs, Inc. on an amended Schedule 13G. They report beneficial ownership of 3,507,502 shares of Crocs common stock, representing 7.1% of the class as of June 30, 2026.
FMR LLC has sole voting power over 3,362,891.33 shares and sole dispositive power over 3,507,502 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over the same 3,507,502 shares and no voting or shared dispositive power.
One or more other persons have the right to receive dividends or sale proceeds from these shares, but no such person has an interest equal to or exceeding five percent of Crocs’ outstanding common stock. Subsidiaries involved in holding the securities are identified in an attached Exhibit 99.